Free Trial

4D Molecular Therapeutics (FDMT) News Today

4D Molecular Therapeutics logo
$3.49 -0.11 (-3.06%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$3.58 +0.09 (+2.72%)
As of 05/23/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT Latest News

4D Molecular Therapeutics, Inc. stock logo
Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Jane Street Group LLC raised its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 143.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 210,824 shares of the company's stock after purchasing an additional 124,
4D Molecular Therapeutics, Inc. stock logo
VR Adviser LLC Decreases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
VR Adviser LLC trimmed its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 32.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,952,371 shares of the
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,252,240 shares of the company's stock after selling 884,847 shares during the perio
4D Molecular Therapeutics, Inc. stock logo
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Dimensional Fund Advisors LP cut its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 36.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 131,965 shares of the company's s
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. stock logo
Cantor Fitzgerald Has Negative View of FDMT FY2025 Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings estimates for 4D Molecular Therapeutics in a note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company w
4D Molecular Therapeutics, Inc. stock logo
HC Wainwright Analysts Raise Earnings Estimates for FDMT
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - HC Wainwright lifted their Q2 2025 earnings estimates for 4D Molecular Therapeutics in a report issued on Monday, May 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.89) per share for the quarter, u
FY2025 Earnings Estimate for FDMT Issued By Chardan Capital
HC Wainwright Analysts Increase Earnings Estimates for FDMT
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald
4D Molecular Therapeutics, Inc. stock logo
Cubist Systematic Strategies LLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Cubist Systematic Strategies LLC lifted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 2,084.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 448,831 shares of the company's stock after purchasing a
4D Molecular Therapeutics, Inc. stock logo
Algert Global LLC Acquires 103,342 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Algert Global LLC lifted its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 140.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 176,778 shares of th
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (E+)" Rating at Weiss Ratings
Weiss Ratings reissued a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday.
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $38.00 Price Target at Barclays
Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research note on Friday.
4D Molecular Therapeutics, Inc. stock logo
Raymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Raymond James Financial Inc. bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 112,904 shares of the company's stock, valued at a
4D Molecular Therapeutics, Inc. stock logo
Deep Track Capital LP Decreases Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Deep Track Capital LP trimmed its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 85.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 609,900 shares of the company's
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued
4D Molecular Therapeutics, Inc. stock logo
Marshall Wace LLP Decreases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Marshall Wace LLP trimmed its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 68.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,744 shares of the company's stock after
4D Molecular Therapeutics, Inc. stock logo
BVF Inc. IL Decreases Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
BVF Inc. IL lessened its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 63.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,670,642 shares of the company's stock after selling 4,712,000 shares during the period. BVF I
4D Molecular Therapeutics, Inc. stock logo
RA Capital Management L.P. Lowers Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
RA Capital Management L.P. lessened its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 10.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,563,211 shares of the company's stock after selling 535,000
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics (FDMT) Expected to Announce Quarterly Earnings on Thursday
4D Molecular Therapeutics (NASDAQ:FDMT) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-4d-molecular-therapeutics-inc-stock/)
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings
Weiss Ratings restated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Thursday.
4D Molecular Therapeutics, Inc. stock logo
JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
JPMorgan Chase & Co. raised its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 159.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 820,069 shares of the company's stock after purc
4D Molecular Therapeutics, Inc. stock logo
Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Vanguard Group Inc. raised its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,860,508 shares of the company's stock after p
4D Molecular Therapeutics, Inc. stock logo
Equities Analysts Offer Predictions for FDMT FY2026 Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Leerink Partnrs issued their FY2026 earnings per share estimates for shares of 4D Molecular Therapeutics in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar anticipates that
4D Molecular Therapeutics, Inc. stock logo
Norges Bank Purchases Shares of 500,823 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Norges Bank acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 500,823 shares of the company's stock, valued at approximately $2,790,000.
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of "Moderate Buy" by Analysts
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. stock logo
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Tuesday.
4D Molecular Therapeutics, Inc. stock logo
Raymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
Raymond James Financial Inc. bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 112,904 shares of the compan
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. stock logo
Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
Weiss Ratings reiterated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday.
4D Molecular Therapeutics, Inc. stock logo
Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Decreases By 15.1%
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 5,240,000 shares, a decline of 15.1% from the February 13th total of 6,170,000 shares. Based on an average daily trading volume, of 906,600 shares, the short-interest ratio is presently 5.8 days. Currently, 12.2% of the company's stock are sold short.
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of "Moderate Buy" from Analysts
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued
4D Molecular Therapeutics, Inc. stock logo
Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price
Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday.
4D Molecular Therapeutics, Inc. stock logo
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss Ratings
Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday.
4D Molecular Therapeutics, Inc. stock logo
Cantor Fitzgerald Issues Positive Outlook for FDMT Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst J. Sc
4D Molecular Therapeutics, Inc. stock logo
Q1 Earnings Forecast for FDMT Issued By HC Wainwright
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for 4D Molecular Therapeutics in a research report issued on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the compan
Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

FDMT Media Mentions By Week

FDMT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FDMT
News Sentiment

1.37

0.75

Average
Medical
News Sentiment

FDMT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FDMT Articles
This Week

4

4

FDMT Articles
Average Week

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners